<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431013</url>
  </required_header>
  <id_info>
    <org_study_id>DDI-103</org_study_id>
    <nct_id>NCT02431013</nct_id>
  </id_info>
  <brief_title>Cilostazol-Simvastatin Drug Interaction Study</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Parallel Study to Investigate The Effect of Cilostazol on the Disposition of Simvastatin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single &amp; multiple-dose, parallel study to investigate the
      effect of cilostazol on the disposition of simvastatin &amp; pravastatin in healthy male
      volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility for participation of this study will be determined from demographic information,
      medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests
      within 4 weeks before study drug administration. Subjects suitable for this study will be
      admitted to the Clinical Trial Center of Ajou University Medical Center on the day before
      dosing (Day -1).

      On Day 1, Subjects will be dosed simvastatin 40 mg or pravastatin 20 mg. Pharmacokinetic
      samplings and blood pressure/pulse rate measurement will be done upto 24 hours after dosing.

      From Day 2 ~ 7, Subjects will be dosed cilostazol 100 mg twice a day. On Day 8, Subjects will
      be dosed simvastatin 40 mg or pravastatin 20 mg with cilostazol 100 mg twice a day.
      Pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 24
      hours after dosing.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (area under the time-concentration curve) of Simvastatin</measure>
    <time_frame>up to 12 hours after Simvastatin dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration) of Simvastatin</measure>
    <time_frame>up to 12 hours after Simvastatin dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration) of Pravastatin</measure>
    <time_frame>up to 12 hours after Pravastatin dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the time-concentration curve) of Pravastatin</measure>
    <time_frame>up to 12 hours after Pravastatin dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Simvastatin+Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin+Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 40 mg on Day 1 &amp; Day 8.</description>
    <arm_group_label>Simvastatin+Cilostazol</arm_group_label>
    <other_name>S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Pravastatin 20 mg on Day 1 &amp; Day 8.</description>
    <arm_group_label>Pravastatin+Cilostazol</arm_group_label>
    <other_name>P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol 100 mg twice a day for 6 days &amp; on Day 8 with statin.</description>
    <arm_group_label>Simvastatin+Cilostazol</arm_group_label>
    <arm_group_label>Pravastatin+Cilostazol</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 20 - 45 years

          -  With in 20% of ideal body weight, {Ideal body weight=[height(cm)-100]*0.9}

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic,
             gastrointestinal disease or mental disorder (Past history or present)

          -  Inadequate result of laboratory test (especially, AST/ALT &gt; 1.25 x UNL, Total
             bilirubin &gt; 1.5 x UNL)

          -  Positive reaction in the HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL test

          -  Taking OTC(Over the counter)medicine including oriental medicine within 7 days

          -  Clinically significant allergic disease (Except for mild allergic rhinitis and
             dermatitis seems to be not need for medication)

          -  Subject with known for hypersensitivity reaction to Cilostazol, Simvastatin or
             Pravastatin

          -  Previous whole blood donation within 60 days or component blood donation within 30
             days

          -  Previous participation of other trial within 90 days

          -  Continued taking caffeine (caffeine &gt; 5 cup/day), drinking (alcohol &gt; 30 g/day) and
             severe heavy smoker (cigarette &gt; 1/2 pack per day)

          -  An impossible one who participates in clinical trial by investigator's decision
             including for reason of laboratory test result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doo-Yeoun Cho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doo-Yeoun Cho, MD</last_name>
    <phone>+82-31-219-4271</phone>
    <email>dooycho@ajou.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi</state>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doo-Yeoun Cho, MD</last_name>
      <phone>+82-31-219-4271</phone>
      <email>dooycho@ajou.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Doo-Yeoun Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Doo-Yeoun Cho</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

